Form 4 Filing for Aligos Therapeutics, Inc. - Ownership Change

This filing reports a change in beneficial ownership for Peter Hirth, a director at Aligos Therapeutics, Inc. (ALGS). On June 25, 2026, Hirth acquired 5,860 stock options with a right to buy common stock. These options have an exercise price of $5.50 and are set to expire on June 25, 2036. The shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately prior to the 2027 annual meeting, contingent upon continued service. The transaction was reported on June 29, 2026. This indicates a stock option grant to an insider.